BLA 103575 · Centocor INC
Reopro
Abciximab · Injection
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Aug 7, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1994
Dec 22, 1994
Approved uses
4
Original approval plus efficacy supplements
Registered trials
51
17 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 23, 2001 Supplement 1015 · Efficacy
- Nov 5, 1997 Supplement 1008 · Efficacy · priority review ReviewLetterLabel
- Nov 5, 1997 Supplement 1010 · Efficacy · priority review LabelReviewLetter
- Dec 22, 1994 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- REOPRO · ABCIXIMAB 2MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Abciximab" as an intervention, any sponsor and status, largest first.
Boehringer IngelheimBoehringer Ingelheim
NCT02181985 · 5,989 participants · Start May 2000 · Primary completion Apr 2001
Drug: Full dose TNK-tPA; Half dose TNK-tPA and 3 more · For: Myocardial Infarction
- Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)Pivotal-lookingCompleted
Deutsches Herzzentrum MuenchenAcademic, hospital or other
NCT00262054 · 4,570 participants · Start Nov 2005 · Primary completion Feb 2008
Drug: Bivalirudin; Un-fractionated heparin · For: Coronary Disease; Angina Pectoris
Sites: Bad Krozingen, Germany; Bad Segeberg, Germany; Munich, Germany · 4 sites in all
- A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.Pivotal-lookingCompleted
Centocor, Inc.Johnson & Johnson (Janssen) (JNJ)
NCT00269880 · 2,792 participants · Start Feb 1995 · Primary completion Dec 1995
Drug: Placebo; Heparin and 1 more · For: Angioplasty, Transluminal, Percutaneous Coronary
- A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)Pivotal-lookingCompleted
Centocor, Inc.Johnson & Johnson (Janssen) (JNJ)
NCT00046228 · 2,461 participants · Start Aug 2002 · Primary completion Jan 2008
Drug: abciximab placebo; reteplase placebo, abciximab, abciximab; Abciximab; reteplase; abciximab placebo; abciximab and 4 more · For: Myocardial Infarction
Sites: Phoenix, Arizona; Covina, California; Modesto, California · 227 sites in all
- A Study Comparing the Efficacy and Safety of Intracoronary Stenting With or Without Abciximab, an Anti-Platelet Therapy, and Conventional Coronary Angioplasty With AbciximabPivotal-lookingCompleted
Centocor, Inc.Johnson & Johnson (Janssen) (JNJ)
NCT00271401 · 2,399 participants · Start Jul 1996 · Primary completion Sep 1997
Drug: Abxicimab; Heparin and 1 more · For: Angioplasty, Transluminal, Percutaneous Coronary
- European Ambulance Acute Coronary Syndrome (ACS) Angiography TrialPivotal-lookingCompleted
The Medicines CompanyIndustry
NCT01087723 · 2,198 participants · Start Mar 2010 · Primary completion Aug 2013
Drug: Bivalirudin; Heparin · For: Acute Coronary Syndrome
Sites: Vienna, Austria; České Budějovice, Czechia; Aarhus, Denmark · 145 sites in all
- A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary AngioplastyPivotal-lookingCompleted
Centocor, Inc.Johnson & Johnson (Janssen) (JNJ)
NCT00269893 · 2,038 participants · Start Nov 1991 · Primary completion Nov 1992
Drug: Abciximab; Placebo · For: Angina, Unstable; Angioplasty, Transluminal, Percutaneous Coronary
- Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)Pivotal-lookingCompleted
Deutsches Herzzentrum MuenchenAcademic, hospital or other
NCT00133003 · 2,022 participants · Start Mar 2003 · Primary completion Jan 2006
Drug: Abciximab; Placebo · For: Coronary Disease; Angina, Unstable
Sites: São Paulo, Brazil; Bad Krozingen, Germany; Munich, Germany · 5 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Clinical trials of IIb/IIIa receptor blockers in patients undergoing angioplasty.
Mathew TP, Adgey AA · Semin Interv Cardiol 1999 · Meta-Analysis
- A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia.
Arnold DM, Kukaswadia S, Nazi I, et al. · J Thromb Haemost 2013 · Research Support, Non-U.S. Gov't, Systematic Review
- Antithrombotic effects of abciximab.
Hayes R, Chesebro JH, Fuster V, et al. · Am J Cardiol 2000 · Clinical Trial, Comparative Study
- Efficacy and safety of early versus late glycoprotein IIb/IIIa inhibitors for PCI.
Xu Q, Yin J, Si LY · Int J Cardiol 2013 · Meta-Analysis
- Soluble CD40 ligand in acute coronary syndromes.
Heeschen C, Dimmeler S, Hamm CW, et al. · N Engl J Med 2003 · Clinical Trial, Randomized Controlled Trial
- Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment.
Dörffler-Melly J, Koopman MM, Prins MH, et al. · Cochrane Database Syst Rev 2005 · Meta-Analysis, Systematic Review
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.